Article
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
The Journal of infectious diseases - 1 Sept 2010
Ribaudo Heather J, Liu Huan, Schwab Matthias, Schaeffeler Elke, Eichelbaum Michel, Motsinger-Reif Alison A, Ritchie Marylyn D, Zanger Ulrich M, Acosta Edward P, Morse Gene D, Gulick Roy M, Robbins Gregory K, Clifford David, Haas David W
Abstract excerpt
In AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
